NHIA Expands Cover to Cut Cancer Treatment Costs

 

Nigeria’s National Health Insurance Authority (NHIA) has announced an expanded health insurance framework designed to dramatically slash out-of-pocket expenses for cancer diagnosis, radiotherapy, and targeted oncology medications across the country.

The new policy package, rolled out by the authority to mark Breast Cancer Awareness Month, introduces an 80% cost-reduction scheme for essential cancer medications, alongside increased financial subsidies for radiotherapy treatments ranging from ₦400,000 to complete bill coverage for eligible beneficiaries.

A Public-Private Cost-Sharing Benchmark

At the center of the expanded coverage is a co-financing partnership between the NHIA and global pharmaceutical leader Roche. Under this tripartite agreement, Swiss drugmaker Roche absorbs 50% of the market cost for high-value oncology drugs. The NHIA subsidizes an additional 30%, leaving eligible enrollees responsible for paying just 20% of the total retail price at accredited health facilities nationwide.

This measure directly targets the phenomenon of financial toxicity where the exorbitant expense of lifesaving oncology treatments pushes families into severe poverty, debt, or premature cessation of care.

Speaking on the shift in policy direction, NHIA Director-General and Chief Executive Officer, Dr. Kelechi Ohiri, emphasized that the true benchmark of a national health system lies in the quality of financial risk protection offered during severe health crises.

“The critical measure of the insurance system should no longer be the number of Nigerians carrying insurance records, but whether those records provide meaningful protection when illness strikes,” Dr. Ohiri stated.

He underscored that high-cost illnesses like cancer require sustained interventions across multiple stages of care, including diagnostic scans, repeated chemotherapy cycles, advanced radiation therapy, and post-treatment monitoring.

Addressing the High Cost of Radiotherapy and Diagnostics

Beyond drug subsidies, the NHIA’s revised benefits package expands direct financial support for radiation oncology. Radiotherapy, which is required by up to 50% of cancer patients during their treatment course, remains one of the most expensive out-of-pocket medical expenses in Nigerian tertiary hospitals.

Under the upgraded provisions, the authority has instituted targeted grants ranging from ₦400,000 per patient to full coverage for patients undergoing radiotherapy at recognized federal medical centers and specialist teaching hospitals. The scheme also extends coverage for diagnostic investigations, including advanced imaging scans and pathology tests necessary for early staging and treatment tracking.

Healthcare providers and oncology advocates have widely welcomed the policy update. For years, medical experts have warned that high costs cause late-stage presentation and high dropout rates among Nigerian patients. Chemotherapy regimens, which can easily cost hundreds of thousands of Naira per session, routinely force households to liquidate assets or rely on crowdfunding.

The co-funding model aims to ensure that once a patient is diagnosed, financial insolvency does not stop them from completing their full treatment regimen.

Integrating National Cancer Care Frameworks

The NHIA's expanded coverage aligns with the broader objectives of the Federal Ministry of Health’s National Cancer Control Plan (2026–2030). This strategic framework focuses on building equitable oncology infrastructure, promoting early detection screenings, and integrating comprehensive cancer management into social health insurance schemes.

Nigeria faces a heavy cancer burden, with tens of thousands of new cases recorded annually predominantly breast, cervical, and prostate cancers. Public health officials have repeatedly highlighted that early detection combined with accessible treatment provides the highest probability of clinical survival.

While health experts describe the NHIA's expanded 80% drug coverage and radiotherapy subsidies as a pivotal step toward Universal Health Coverage (UHC), stakeholders note that implementation efficiency will be crucial. Key priorities moving forward include streamlining administrative processing times for claims, expanding the roster of participating oncology drugs, and ensuring consistent supply chains across all geopolitical zones.

Dr. Ohiri reiterated the authority’s commitment to refining and expanding its critical care benefits, calling on uninsured Nigerians to enroll in national and state health insurance schemes. By shielding families from catastrophic health expenditures, the NHIA aims to transform cancer care from a financially ruinous diagnosis into a manageable medical condition accessible to all Nigerians.